MedMiraJan 311 minPublic InformationThe Company planned to issue a Press Release with a commercial update this month. Due to a highly positive change in the commercial...
MedMiraJan 113 minMedMira receives CE mark for its VYRA™ CoV2Flu Antigen TestHalifax, Nova Scotia, 11 January, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of the CE mark for its VYRA™...
MedMiraJan 51 minMedMira's G4 HIV (FDA approved) rapid test - an independent evaluation by the CDCPerformance Evaluation of the MedMira Reveal G4 LAB S/P and POC HIV Antibody Rapid Screening Tests using Plasma and Whole Blood Specimens...
MedMiraJan 34 minPoint-of-Care Diagnostic for Trichomonas vaginalis based on MedMira’s RVF Technology®Halifax, Nova Scotia, 3 January, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the publication of Point-of-Care Diagnostic...
MedMiraJan 34 minPoint-of-Care Diagnostic for Trichomonas vaginalis based on MedMira’s RVF Technology®Halifax, Nova Scotia, 3 January, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the publication of Point-of-Care Diagnostic...
MedMiraDec 29, 20223 minMedMira Introduces VYRA TriDemicHalifax, Nova Scotia, 29 December, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) presents its latest addition to the VYRATMproduct...